ABUS - Arbutus Biopharma Corporation

Healthcare - Sector
Coverage

ABUS is currently covered by 5 analysts with average potential upside of $2.16 (54.37%) backed by 31 price targets and 43 ratings. Analyst's average stock valuation to be materialised ratio is 46.84% with an average time for price targets to be met of 63.14 days.

Most recent stock forecast was given by DENNIS DING from JEFFERIES on 03-Feb-2022.

Highest price target for ABUS is 4, Lowest price target is 3, average price target is 3.5.

Best performing analysts who are covering ABUS - Arbutus Biopharma Corporation:

Gbola Amusa Robert Driscoll Madhu Kumar Keay Nakae Liisa Bayko Mayank Mamtani Dennis Ding

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Buy

5

$2.05 (69.49%)

4

1 years 1 days ago

0/3 (0%)

$1.22 (39.59%)

Buy

5

$2.05 (69.49%)

5

1 years 2 months 2 days ago

3/5 (60%)

$1.02 (33.22%)

59

Buy

7

$4.05 (137.29%)

7

1 years 7 months 7 days ago

0/4 (0%)

$4.08 (92.75%)

Buy

7

$4.05 (137.29%)

8

1 years 10 months 25 days ago

1/4 (25%)

$3.58 (92.40%)

196

Buy

6

$3.05 (103.39%)

5

1 years 10 months 27 days ago

4/7 (57.14%)

$2.38 (45.99%)

34

Show more analysts